Dr. Lisa Anderson, President of Paragonix Technologies. “This achievement validates our technology’s safety and effectiveness while expanding our ability to serve patients and healthcare providers in critical transplant care across the world. With this approval and the support structure provided by Sweden-based Getinge, we are dedicated to setting new standards in organ preservation, advancing the future of transplantation, and making a global impact.”

Following weeks of in-hospital monitoring, the patient was the first in the world to be discharged from the hospital with the BiVACOR Total Artificial Heart as he awaited a heart transplant. After having the device for 105 days, a donor heart became available, and the patient received a heart transplant on March 6, 2025.

Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery.

Isa Rizk, Co-Founder and CEO of Reflow Medical. “This presence allows us to better address the needs of international markets by providing direct sales solutions and forming key distribution collaborations. Our goal is to deliver breakthrough technologies that support physicians and improve patient outcomes worldwide.”